Liquidia

Liquidia shares dropped after a US court sided with United Therapeutics in a patent dispute between the two pharmaceutical companies. The ruling is a setback for Liquidia, whose lead product competes with United Therapeutics' treatments for pulmonary arterial hypertension. Investors reacted quickly, sending the stock lower as the market assessed the implications for Liquidia's commercial prospects.

Liquidia shares collapsed 57% in a single trading day following a ruling by a Delaware court, wiping out a large portion of the biotech's market value. Investors are now watching whether an appeal could reverse the decision and allow the stock to recover. The case centers on a legal dispute with implications for the company's key product.

Liquidia's stock fell sharply following a court ruling in its long-running patent dispute with United Therapeutics over its lead pulmonary hypertension drug. The litigation, centered on United Therapeutics' claims that Liquidia infringed patents tied to treprostinil therapies, has weighed on the company for years, and investors reacted quickly to the latest adverse development in court.